The exopolysaccharide of the bacterium SHIGELLA SONNEI, THE WAY OF ITS OBTAINING AND INCLUDING ITS VACCINE AND PHARMACEUTICAL COMPOSITION

摘要

The O-specific polysaccharide antigen, exopolysaccharide of Shigella sonnei bacterium, phase I, representing an authentic natural compound, bacterial capsular polysaccharide, consisting of 1-100 repeating disaccharide units of O- [4-amino-2- (N-acetyl), was obtained and characterized for the first time. amino-2,4-dideoxy-β-D-galactopyranosyl] - (1 → 4) -O- [2- (N-acetyl) amino-2-deoxy-α-L-altrpyranuronic acid], connected in a polysaccharide chain ( 1 → 3) connections. Exopolysaccharide has a molecular weight of 0.4 to 400 kDa, contains a non-toxic lipid component — non-hydroxylated fatty acids, and exhibits low pyrogenicity and high immunogenicity, causing mucosal protection from Sonne's Schigellosis by inducing the synthesis of specific antibodies against S. sonnei in mammals, including humans . High purity exopolysaccharide is obtained without using lipopolysaccharides as a source of its production in an industrially technologically efficient way from the liquid phase of the culture of S. sonnei bacteria in high yield. Based on the exopolysaccharide, effective, highly specific and safe vaccines have been developed for the prevention and / or treatment of Sonne shigellosis, as well as pharmaceutical compositions with a broad spectrum of action, in particular, modulating the immune system response.